EUFOREA, the European Forum for Research and Education in Allergy and Airways diseases, is an international non-for-profit organisation of physicians, patients, and other stakeholders committed to the improvement of outcomes for patients suffering from chronic inflammatory respiratory conditions through collaborative research, education, and targeted advocacy. In February 2025, EUFOREA hosted its biennial summit in Brussels, convening expert panels, its Patient Advisory Board, and a range of leadership representatives. This event was pivotal in establishing the research, educational, and advocacy priorities for the subsequent 2-year period, coinciding with the organisation's 10th anniversary in April 2025. Building on its core competencies, EUFOREA advances evidence-based clinical tools and educational initiatives designed to narrow the gap between emerging science and routine care. In alignment with the objective of enhancing global healthcare standards, the specialists' panels of chronic rhinosinusitis and European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergic rhinitis, asthma, allergen immunotherapy, and paediatrics have devised and detailed a comprehensive range of initiatives that address significant unmet needs within the domains of allergy and respiratory care. This document presents a summary of EUFOREA's future objectives, aspirations, and strategy, providing a clear direction for the coming years. It serves as a valuable resource for individuals and organisations involved in both the allergy and the respiratory sectors, offering a comprehensive overview of the association's plans and initiatives.
Lau et al. (Fri,) studied this question.